IP Library Granted Patent US 7,858,765
Granted Patent B2
US 7,858,765 · App. 12/624,534 · Granted Dec 28, 2010

OX40R binding agents

Assignee: Merck Serono SA
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,858,765
App. No.
12/624,534
Granted
Dec 28, 2010
Kind
B2
Abstract

The present invention discloses peptides isolated from the extracellular domain of OX40 Ligand (OX40L) capable of binding OX40 Receptor (OX40R) and inhibiting OX40R-OX40L interaction. Such peptides, fusion proteins comprising them, as well as peptides and other molecules designed on their sequences, can be used as OX40R binding agents competing with natural OX40L for blocking OX40R-mediated cell signaling in the prophylaxis and/or treatment of diseases related to activated T cells.

Claims (36)

1. An isolated nucleic acid encoding a polypeptide consisting of:

a) SEQ ID NO: 6;

b) SEQ ID NO: 6, wherein one or more amino acids have been deleted, said polypeptide contains SEQ ID NO: 13 and said polypeptide binds to the OX40 receptor (OX40R);

c) between 5 and 10 contiguous amino acids of SEQ ID NO: 1, wherein said polypeptide contains SEQ ID NO: 13 and binds to OX40R;

d) SEQ ID NO: 8 or SEQ ID NO: 13;

e) an active mutant of a), b), c) or d), wherein one or more of the amino acids has been conservatively substituted and said active mutant binds to OX40R; or

f) a fusion polypeptide or peptide comprising a first amino acid sequence and a second amino acid sequence, wherein said first amino acid sequence is a protein sequence other than human OX40L fused to a second amino acid sequence selected from:

i) SEQ ID NO: 6;

ii) SEQ ID NO: 6, wherein one or more amino acids have been deleted, said second amino acid sequence contains SEQ ID NO: 13 and said fusion polypeptide binds to the OX40 receptor (OX40R);

iii) between 5 and 10 contiguous amino acids of SEQ ID NO: 1, wherein said contiguous amino acids of SEQ ID NO: 1 contain SEQ ID NO: 13 and said fusion polypeptide binds to OX40R; or

iv) SEQ ID NO: 8 or SEQ ID NO: 13.

2. The isolated nucleic acid according to claim 1 , wherein said nucleic acid encodes a fusion polypeptide or peptide that comprises an amino acid sequence selected from one or more of the following protein sequences: membrane-bound proteins, extracellular domains of membrane-bound protein, immunoglobulin constant region, multimerization domains, extracellular proteins, signal peptide-containing proteins or export signal-containing proteins.

3. The isolated nucleic acid according to claim 1 , wherein said nucleic acid encodes a polypeptide consisting of SEQ ID NO: 6.

4. The isolated nucleic acid according to claim 1 , wherein said nucleic acid encodes a polypeptide consisting of SEQ ID NO: 6, wherein one or more amino acids have been deleted, said polypeptide contains SEQ ID NO: 13 and said polypeptide binds to the OX40 receptor (OX40R).

5. The isolated nucleic acid according to claim 1 , wherein said nucleic acid encodes a polypeptide consisting of between 5 and 10 contiguous amino acids of SEQ ID NO: 1, containing SEQ ID NO: 13 and binding to OX40R.

6. The isolated nucleic acid according to claim 1 , wherein said nucleic acid encodes a polypeptide consisting of SEQ ID NO: 8.

7. The isolated nucleic acid according to claim 1 , wherein said nucleic acid encodes a polypeptide consisting of SEQ ID NO: 13.

8. The isolated nucleic acid according to claim 1 , wherein said nucleic acid encodes a polypeptide consisting of an active mutant of a), b), c) or d), wherein three or fewer amino acids are conservatively substituted and said active mutant binds to OX40R.

9. The isolated nucleic acid according to claim 1 , wherein said nucleic acid encodes a fusion polypeptide or peptide and said second amino acid sequence is a peptide consisting of SEQ ID NO: 6.

10. The isolated nucleic acid according to claim 1 , wherein said nucleic acid encodes a fusion polypeptide or peptide and said second amino acid sequence is SEQ ID NO: 6, wherein one or more amino acids have been deleted, said polypeptide contains SEQ ID NO: 13 and said fusion polypeptide or peptide binds to the OX40 receptor (OX40R).

11. The isolated nucleic acid according to claim 1 , wherein said nucleic acid encodes a fusion polypeptide or peptide and said second amino acid sequence is a peptide consisting of between 5 and 10 contiguous amino acids of SEQ ID NO: 1 that contains SEQ ID NO: 13 and said fusion polypeptide or peptide binds to OX40R.

12. The isolated nucleic acid according to claim 1 , wherein said nucleic acid encodes a fusion polypeptide or peptide and said second amino acid sequence is a peptide consisting of SEQ ID NO: 8 or SEQ ID NO: 13.

13. The isolated nucleic acid according to claim 1 , wherein said nucleic acid encodes a polypeptide that antagonizes the activity of OX40R.

14. A vector comprising the nucleic acid according to claim 1 .

15. A host cell comprising a nucleic acid according to claim 1 .

16. A method of making a polypeptide comprising culturing the host cell according to claim 15 under conditions that allow for the production of a polypeptide consisting of:

a) SEQ ID NO: 6;

b) SEQ ID NO: 6, wherein one or more amino acids have been deleted, said polypeptide contains SEQ ID NO: 13 and said polypeptide binds to the OX40 receptor (OX40R);

c) between 5 and 10 contiguous amino acids of SEQ ID NO: 1, wherein said polypeptide contains SEQ ID NO: 13 and binds to OX40R;

d) SEQ ID NO: 8 or SEQ ID NO: 13;

e) an active mutant of a), b), c) or d), wherein one or more of the amino acids has been conservatively substituted and said active mutant binds to OX40R; or

f) a fusion polypeptide or peptide comprising a first amino acid sequence and a second amino acid sequence, wherein said first amino acid sequence is a protein sequence other than human OX40L fused to a second amino acid sequence selected from:

i) SEQ ID NO: 6;

ii) SEQ ID NO: 6, wherein one or more amino acids have been deleted, said second amino acid sequence contains SEQ ID NO: 13 and said fusion polypeptide binds to the OX40 receptor (OX40R);

iii) between 5 and 10 contiguous amino acids of SEQ ID NO: 1, wherein said contiguous amino acids of SEQ ID NO: 1 contain SEQ ID NO: 13 and said fusion polypeptide binds to OX40R; or

iv) SEQ ID NO: 8 or SEQ ID NO: 13.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 8, 2010
From: SOTO-JARA, CLAUDIO; PENA-ROSSI, CLAUDIA
To: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.
Reel/Frame 024497/0949 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 8, 2010
From: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.
To: LABORATOIRES SERONO SA
Reel/Frame 024497/0953 →
CHANGE OF NAME Recorded Jun 8, 2010
From: LABORATOIRES SERONO SA
To: MERCK SERONO SA
Reel/Frame 024498/0103 →
Priority Claims (1)
EP 02100334 · Apr 3, 2002 · regional
Continuity (2)
Division 1051001500
Related Publication 20100136628A1 · Jun 3, 2010